...and the rest

The Mail on Sunday

Britons love sparkling wine, quaffing 215 million bottles of the stuff every year. Of that total just six million are made here, but interest in English wine is growing as climate change makes for balmier British weather. Kent-based winery Chapel Down already accounts for 38% of the UK market. The shares have “more than tripled over the past decade” but there “should be plenty more” fizz to come, so hold (72p).

Interactive Investor

Electrical retailer Currys has had a “rotten couple of years”, but on a forward price/ earnings (p/e) multiple of just 5.7 the shares trade at a sizeable discount to comparable peers such as AO World. Yet thin operating margins and a shaky outlook for consumer demand are reasons for caution. Hold (51p).

Investors’ Chronicle

Trading is still “ticking along” at luxury timepiece play Watches of Switzerland. There is still a big growth opportunity in the US and in second-hand dealing, while on a forward p/e of 12 the shares are on a discount to the five-year average of 18. Buy (653p).

The Telegraph

Pharmaceutical giant AstraZeneca boasts an “excellent track record” and an earnings outlook that is the envy of most other FTSE firms.

A diversified drug pipeline raises the odds of finding future drug champions, while research and development (R&D) spending is rising. Buy (10,468p).

The Times

Shares in AI computer chip specialist Nvidia have surged by 240% in 2023 but there could be more to come. Hugely impressive earnings growth means that the p/e has fallen to 25. With a “first-mover advantage” in AI, there is more scope for profit growth. Buy ($482).